Spectral Diagnostics Inc. (OTCMKTS:EDTXF – Get Free Report) traded down 1.7% on Wednesday . The company traded as low as $0.9241 and last traded at $0.9241. Approximately 4,000 shares changed hands during trading, a decline of 58% from the average daily volume of 9,423 shares. The stock had previously closed at $0.94.
Spectral Diagnostics Stock Performance
The company has a market capitalization of $271.62 million, a P/E ratio of -9.24 and a beta of 0.16. The firm has a 50 day moving average price of $0.97 and a two-hundred day moving average price of $0.99.
About Spectral Diagnostics
Spectral Medical Inc focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, and internationally. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops and manufactures monoclonal and polyclonal antibodies, recombinant cardiac proteins, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies.
See Also
- Five stocks we like better than Spectral Diagnostics
- Striking Oil: How the U.S. Play for Venezuela Fuels Supermajors
- J.M. Smucker Stock’s Rally Has More Than Tariffs Behind It
- Wendy’s Rally Fades After Trian Steps Back: Was It Ever Real?
- GitLab’s Earnings Beat Just Gave Software Bulls a New SaaSpocalypse Test
Receive News & Ratings for Spectral Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectral Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
